跳到正文
原文
Medical Xpress·· 2026-10-14精选AI 评分64

OSUCCC-led Phase I trial of trispecific CAR T-cell therapy shows early promise for B-cell cancers in first-in-human setting

Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

AI 导读

The Ohio State University researchers conducted a Phase I trial testing trispecific CAR T-cell therapy targeting CD19。

推荐理由

原文明确给出 I 期试验的入组人数、靶点组合及临床缓解情况,读者可据此了解该疗法的早期安全性与有效性证据层级。

正文 · 原文
Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial
Immunophenotypic and functional characteristics of CD8+ CAR+ T cells and CD4+ CAR+ T cells in trispecific CAR T infusion products. Patient’s trispecific CAR T infusion products were analyzed via spectral flow cytometry. Credit: Blood Cancer Discovery (2026). DOI: 10.1158/2643-3230.bcd-26-0186

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers. The findings are published in Blood Cancer Discovery.

Researchers were able to build on earlier work done at Ohio State that used CAR T-cell therapy to enhance treatment of B-cell blood cancers. About half of all blood cancers are B-cell blood cancers, including lymphoma and some leukemias.

This trial tested CAR T-cell therapy targeting three proteins—CD19, CD20 and CD22—and used a different protein called OX40 to boost immune response in patients.

"This was the first time a CAR T-cell clinical trial used OX-40 to enhance the process and improve tumor death," said the study's first and corresponding author Sumithira Vasu, M.D., professor of hematology and member of the Leukemia and Hematologic Malignancies (LHM) Program at the OSUCCC—James. "Results from our trial could lead to better therapeutic outcomes for patients who may have limited options after their B-cell blood cancer has returned or their therapy stopped working."

The team also used a faster process to collect, prepare and return the cells to the patient in just six days. This resulted in positive outcomes with minimal side effects for the patients.

"It has been suggested that fresh cell infusions are preferable, and we were able to show feasibility of rapid manufacturing time and infusion of the fresh cells," said lead senior co-author Lapo Alinari, M.D., Ph.D., associate professor of hematology and member of the LHM Program at Ohio State. "This resulted in meaningful clinical activity with minimal side effects in B-cell non-Hodgkin lymphoma, and remission in mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma."

How does CAR T-cell therapy work?

CAR T-cell therapy removes cancer-fighting T cells from the patient's immune system, modifies those cells in a lab to strengthen their ability to kill cancer cells and returns the cells to the patient via an infusion.

The cell therapy typically targets the CD19 protein that plays a large role in B-cell blood cancers. In previous animal studies, scientists at other institutions developed a CAR T-cell therapy that also targeted two additional proteins—CD20 and CD22—and it showed increased effectiveness.

"Even though CAR T-cell therapy has revolutionized therapy for patients with B-cell blood cancers with high rates of remission, many patients will relapse after CAR T-cell therapy, and often within the first year," said Vasu. "Patients are then left with limited treatment options."

Eighteen patients with a median age of 64 were enrolled in the clinical trial, and 16 were treated with the OX-40 protein to enhance the CAR T-cell process. All enrolled patients had previously received a median of three types of therapy before receiving the enhanced cell therapy.

"While our trial showed encouraging outcomes for patients with B-cell non-Hodgkin lymphoma who were treated with our enhanced CAR T-cells, more research in larger patient groups is needed," said senior co-author Marcos de Lima, M.D., professor of hematology at Ohio State.

Publication details

Sumithira Vasu et al., Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22, Blood Cancer Discovery (2026). DOI: 10.1158/2643-3230.bcd-26-0186

Journal information: Blood Cancer Discovery

Who's behind this story?

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-car-cell-therapy-early-cancers.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com